ADCT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors...

Stats
Today's Volume	321 167
Average Volume	707 477
Market Cap	359.41M
EPS	$0 ( 2024-03-13 )
Next earnings date	( $-0.560 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.480
ATR14	$0.00900 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Redmile Group, Llc	Sell	59 986	Cash-settled Swaps
2024-02-01	Redmile Group, Llc	Sell	19 700	Cash-settled Swaps
2024-02-01	Redmile Group, Llc	Buy	205 483	Cash-settled Swaps
2024-01-31	Redmile Group, Llc	Buy	150 000	Cash-settled Swaps
2024-01-29	Redmile Group, Llc	Buy	150 000	Cash-settled Swaps

INSIDER POWER
-45.66
Last 79 transactions
Buy: 1 817 492 \| Sell: 5 217 316

Volume Correlation

Long: -0.02 (neutral)

Short: 0.62 (weak)

Signal:(47.638) Neutral

ADC Therapeutics SA Correlation

10 Most Positive Correlations
K	0.945
NKX	0.942
OGN	0.941
JWN	0.941
SPCE	0.937
ZME	0.936
BIG	0.933
BBWI	0.933
GSL	0.933
USPH	0.931

10 Most Negative Correlations
FLRT	-0.949
SLB	-0.944
CANE	-0.944
OII	-0.943
IEZ	-0.94
OIH	-0.937
WHD	-0.937
HAL	-0.935
AFT	-0.934
BKR	-0.933

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ADC Therapeutics SA Correlation - Currency/Commodity

0.63
( weak )

0.46
( neutral )

0.00
( neutral )

0.59
( weak )

0.00
( neutral )

-0.40
( neutral )

ADC Therapeutics SA Financials

Annual	2023
Revenue:	$69.56M
Gross Profit:	$67.03M (96.36 %)
EPS:	$-2.94

FY	2023
Revenue:	$69.56M
Gross Profit:	$67.03M (96.36 %)
EPS:	$-2.94

FY	2022
Revenue:	$209.91M
Gross Profit:	$205.33M (97.82 %)
EPS:	$-1.990

FY	2021
Revenue:	$33.92M
Gross Profit:	$32.52M (95.89 %)
EPS:	$-3.52

Financial Reports:

No articles found.

ADC Therapeutics SA

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.